# IL-6 Induces CD45 Expression on Myeloid Cells

**Authors:** Maryam Ahmed Al Barashdi, Ahlam Ali, Mary Frances McMullin, Ken Mills

PMC · DOI: 10.18295/2075-0528.2872 · 2025-05-02

## TL;DR

This study shows that IL-6 increases CD45 expression in myeloid leukemia cells, which affects their survival and resistance to chemotherapy.

## Contribution

The study reveals a novel link between IL-6 activation and CD45 expression in myeloid malignancies, impacting chemotherapy response.

## Key findings

- IL-6 enhances survival and proliferation in myeloid leukemia cells.
- CD45 expression correlates with IL-6 activation and chemotherapy resistance.
- Higher CD45 expression leads to greater cytarabine resistance in myeloid cells.

## Abstract

Activation of IL-6 facilitates CD45 expression in myeloma cells, but little has been reported for myeloid malignancies. This study aimed to investigate whether IL-6 enhances CD45 expression on myeloid malignancies and whether myeloid cells are dependent on IL-6 activation to express CD45 on their cell membrane.

This study was conducted from January to March 2022 at the Queen's University Belfast, UK. Myeloid cell lines such as HEL and OCI-AML3 which expressed higher levels of CD45, and UT-7 and the pro-B NALM-6 cell lines that had lower CD45 levels as well as primary cells were used. The correlation between CD45 expression and IL-6 activation in myeloid cells was studied in terms of survival and response to chemotherapy such as cytarabine.

It was found that IL-6 enhances cellular survival in myeloid leukaemia cells. Expression of CD45 could be correlated with IL-6 activation in myeloid leukaemia cells. Quantification of IL-6 confirms the significant effect on cellular proliferation. More importantly, IL-6 significantly alters CD45 expressed myeloid leukaemia cellular response to chemotherapy such as cytarabine.

IL-6 significantly induced alteration to cytarabine cellular response in those cells of higher CD45 expression, while its effect on cells of lower CD45 expression was minimal. This suggests the importance of CD45 in the activation of IL-6 pathway and initiation of cellular proliferation events with its consequences of cytarabine chemo resistance and enhancement of leukaemia cells survival and proliferation by inhibiting the apoptotic activities of cytarabine.

## Linked entities

- **Proteins:** IL6 (interleukin 6), PTPRC (protein tyrosine phosphatase receptor type C)
- **Chemicals:** cytarabine (PubChem CID 6253)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}
- **Diseases:** myeloid malignancies (MESH:D009369), leukaemia (MESH:D015458), myeloma (MESH:D009101)
- **Chemicals:** cytarabine (MESH:D003561)
- **Cell lines:** UT-7 — Homo sapiens (Human), Adult acute megakaryoblastic leukemia, Cancer cell line (CVCL_2233), NALM-6 — Homo sapiens (Human), Adult B acute lymphoblastic leukemia, Cancer cell line (CVCL_0092), HEL — Homo sapiens (Human), Erythroleukemia, Cancer cell line (CVCL_0001), OCI-AML3 — Homo sapiens (Human), Adult acute myelomonocytic leukemia, Cancer cell line (CVCL_1844)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12293515/full.md

---
Source: https://tomesphere.com/paper/PMC12293515